As of November 6, 2026, 6 holders' latest Schedule 13D or 13G filings report owning 5% or more of Eikon Therapeutics Inc. The largest reported stake is The Column Group IV GP, LP's, at 11.6%. 10 filings are on record since February 11, 2026 (Schedule 13D, February 12, 2026).
Sell to companies like Eikon Therapeutics Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Fmr LLC · Sole voting: 5,518,822 · Shared voting: 0 · Sole dispositive: 5,520,152 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-10-07
- · Reporting person: Abu Dhabi Investment Authority · Sole voting: 0 · Shared voting: 1,147,138 · Sole dispositive: 0 · Shared dispositive: 1,147,138 · SCHEDULE 13G/A, 2026-10-02
- · Holder: Fmr LLC · Percent: 9.2% · SCHEDULE 13G/A
- · Holder: Innovation Endeavors III LP · Percent: 5% · SCHEDULE 13G
- · Holder: Perlmutter Roger M · Percent: 5.2% · SCHEDULE 13G
Eikon Therapeutics Inc has 10 Schedule 13D or 13G filings on record since 2026-02-11. 6 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| The Column Group IV GP, LP | 11.6% | 4,460,979 | SCHEDULE 13D, 2026-02-12 | 2026-02-06 |
| Fmr LLC | 10.2% | 5,520,152 | SCHEDULE 13G/A, 2026-10-07 | 2026-09-30 |
| 7.7% | 4,148,519 | SCHEDULE 13G, 2026-02-11 | 2026-02-04 | |
| BlackRock Portfolio Management LLC | 5.5% | 3,002,737 | SCHEDULE 13G, 2026-04-29 | 2026-03-31 |
| 5.2% | 2,893,171 | SCHEDULE 13G, 2026-05-13 | 2026-02-04 | |
| Innovation Endeavors III LP | 5% | 2,723,226 | SCHEDULE 13G, 2026-05-15 | 2026-03-31 |
| Abu Dhabi Investment Authority | 2.1% | 1,147,138 | SCHEDULE 13G/A, 2026-10-02 | 2026-09-30 |
Holding shares or following this stake? See who's behind Eikon Therapeutics Inc and the warning signs.
Free to see. No signup.
Keep reading
More on Eikon Therapeutics Inc and the records around it.
Eikon Therapeutics Inc elsewhere on the record
- IPO filing Feb 2026
- Who owns it
Companies that share a holder
- Foresite Capital Fund IV, L.P. also filed stake reports on 2 other companies: Lyell Immunopharma, Inc. (Aug 2026), Maze Therapeutics, Inc. (Nov 2025)
- Abu Dhabi Investment Authority also filed stake reports on 7 other companies: Jersey Mike's Subs Inc. (Oct 2026), AGL Private Credit Income Fund (Sep 2026), ReNew Energy Global plc (Aug 2026)
- BlackRock Portfolio Management LLC also filed stake reports on 118 other companies: AMERISAFE INC (Nov 2026), BlackRock ETF Trust (Nov 2026), iShares J.P. Morgan EM Local Currency Bond ETF (Nov 2026)
Watch Eikon Therapeutics Inc
Get an email when Eikon Therapeutics Inc files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Eikon Therapeutics Inc?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Eikon Therapeutics Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Eikon Therapeutics Inc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
16 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Fmr LLC | 5,518,822 | 0 | 5,520,152 | 0 | SCHEDULE 13G/A, 2026-10-07 |
| Abigail P. Johnson | 0 | 0 | 5,520,152 | 0 | SCHEDULE 13G/A, 2026-10-07 |
| Abu Dhabi Investment Authority | 0 | 1,147,138 | 0 | 1,147,138 | SCHEDULE 13G/A, 2026-10-02 |
| Platinum Falcon B 2018 RSC Limited | 0 | 1,147,138 | 0 | 1,147,138 | SCHEDULE 13G/A, 2026-10-02 |
The latest filing identifies Eikon Therapeutics Inc by CUSIP 282564103 and gives its principal executive office as 230 HARRIET TUBMAN WAY, MILLBRAE, CA 94030 (SCHEDULE 13G/A, 2026-10-07).
Purpose of Transaction (Item 4)
The Column Group IV GP, LP
The information set forth in Item 3 of this Statement is incorporated herein by reference. The Reporting Persons hold the securities of the Issuer for general investment purposes. The Reporting Persons may, from time to time, depending on prevailing market, economic and other conditions, acquire additional shares of Common Stock or other securities of the Issuer, dispose of any such securities, or engage in discussions with the Issuer concerning such acquisitions or dispositions or further investments in the Issuer. The Reporting Persons intend to review their investment in the Issuer on a continuing basis and, depending upon the price and availability of shares of Common Stock or other securities of the Issuer, subsequent developments affecting the Issuer, the Issuer's business and prospects, other investment and business opportunities available to the Reporting Persons, general stock market and economic conditions, tax considerations and other factors considered relevant, may decide at any time to increase or to decrease the size of their investment in the Issuer in the open market, in privately negotiated transactions, pursuant to 10b5-1 trading plans or otherwise. Except as set forth above, the Reporting Persons have no present plans or intentions which would result in or relate to any of the transactions described in subparagraphs (a) through (j) of Item 4 of Schedule 13D.Item 4 of the SCHEDULE 13D filed 2026-02-12
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2026-02-11 | James B. Tananbaum | 7.7% | SCHEDULE 13G |
| 2026-02-12 | The Column Group IV GP, LP | 11.6% | SCHEDULE 13D |
| 2026-02-18 | Abu Dhabi Investment Authority | 5.2% | SCHEDULE 13G |
| 2026-04-29 | BlackRock Portfolio Management LLC | 5.5% | SCHEDULE 13G |
| 2026-05-06 | Fmr LLC | 7.1% | SCHEDULE 13G |
| 2026-05-13 | Perlmutter Roger M | 5.2% | SCHEDULE 13G |
| 2026-05-15 | Innovation Endeavors III LP | 5% | SCHEDULE 13G |
| 2026-08-06 | Fmr LLC | 9.2% | SCHEDULE 13G/A |
| 2026-10-02 | Abu Dhabi Investment Authority | 2.1% | SCHEDULE 13G/A |
| 2026-10-07 | Fmr LLC | 10.2% | SCHEDULE 13G/A |
Questions about who owns Eikon Therapeutics Inc
Who owns Eikon Therapeutics Inc?
On this page, 6 holders' latest ownership filings report 5% or more of Eikon Therapeutics Inc: The Column Group IV GP, LP (11.6%, Schedule 13D, filed 2026-02-12), Fmr LLC (10.2%, Schedule 13G/A, filed 2026-10-07), James B. Tananbaum (7.7%, Schedule 13G, filed 2026-02-11), BlackRock Portfolio Management LLC (5.5%, Schedule 13G, filed 2026-04-29) and Perlmutter Roger M (5.2%, Schedule 13G, filed 2026-05-13); 1 more is listed above.
Who are the largest shareholders of Eikon Therapeutics Inc?
By the share each holder's latest filing reports, the largest holders of Eikon Therapeutics Inc on this page are The Column Group IV GP, LP (11.6%), Fmr LLC (10.2%) and James B. Tananbaum (7.7%).
When did The Column Group IV GP, LP buy into Eikon Therapeutics Inc?
The filings give report dates, not purchase dates. The earliest filing from The Column Group IV GP, LP on this page is the Schedule 13D, filed 2026-02-12, reporting 11.6%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 10 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Eikon Therapeutics Inc
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 3, 2026 | Leadership change filing (Form 8-K, Item 5.02) | — | Leadership changes | Source |
| June 10, 2026 | Leadership change filing (Form 8-K, Item 5.02) | — | Leadership changes | Source |
| February 5, 2026 | IPO filing, Form 424B4 | $18 a share | IPO filings | Source |
| January 28, 2026 | IPO filing, Form S-1/A | — | IPO filings | Source |
| January 9, 2026 | IPO filing, Form S-1 | — | IPO filings | Source |
| February 28, 2025 | Form D, private offering | $350.70M sold | Form D page | Source |
Tools for this story
Each opens in a new tab, filled in for Eikon Therapeutics Inc. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.